PE20091838A1 - Inhibidores de amida hidrolasa de acido graso - Google Patents

Inhibidores de amida hidrolasa de acido graso

Info

Publication number
PE20091838A1
PE20091838A1 PE2009000498A PE2009000498A PE20091838A1 PE 20091838 A1 PE20091838 A1 PE 20091838A1 PE 2009000498 A PE2009000498 A PE 2009000498A PE 2009000498 A PE2009000498 A PE 2009000498A PE 20091838 A1 PE20091838 A1 PE 20091838A1
Authority
PE
Peru
Prior art keywords
amida
fatty acid
hydrolase inhibitors
inhibitors
halogen
Prior art date
Application number
PE2009000498A
Other languages
English (en)
Inventor
Mark L Behnke
Alfredo C Castro
Catherine A Evans
Michael J Grogan
Tao Liu
Daniel A Snyder
Louis Grenier
Original Assignee
Infinity Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40912141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091838(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Infinity Pharmaceuticals Inc filed Critical Infinity Pharmaceuticals Inc
Publication of PE20091838A1 publication Critical patent/PE20091838A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN COMPUESTO DE FORMULA III, DONDE Z1 Y Z2 SON DE PREFERENCIA OH; W1 Y W2 SON CADA UNO C, N, CH, ENTRE OTROS; X ES UN ENLACE COVALENTE, -O, -CN.-S-, ENTRE OTROS; RA ES H, HALOGENO, CF3, CN, ENTRE OTROS; R1 ES HALOGENO, CF3, CN, NO2, ENTRE OTROS; n ES 0-3. DICHOS COMPUESTOS SON INHIBIDORES DE ANANDAMIDA AMIDOHIDROLASA UTIL EN EL TRATAMIENTO DE DOLOR, ANSIEDAD, DEPRESION, ENTRE OTROS
PE2009000498A 2008-04-09 2009-04-08 Inhibidores de amida hidrolasa de acido graso PE20091838A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4368608P 2008-04-09 2008-04-09

Publications (1)

Publication Number Publication Date
PE20091838A1 true PE20091838A1 (es) 2009-12-18

Family

ID=40912141

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000498A PE20091838A1 (es) 2008-04-09 2009-04-08 Inhibidores de amida hidrolasa de acido graso

Country Status (12)

Country Link
US (2) US8957049B2 (es)
EP (1) EP2282742A1 (es)
JP (1) JP5637982B2 (es)
CN (1) CN102046179B (es)
AR (1) AR072249A1 (es)
AU (1) AU2009233711B2 (es)
CA (1) CA2721060A1 (es)
CL (1) CL2009000870A1 (es)
IL (1) IL208536A0 (es)
PE (1) PE20091838A1 (es)
TW (1) TW201000107A (es)
WO (1) WO2009126691A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP2282742A1 (en) 2008-04-09 2011-02-16 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
CA2757622A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010124113A1 (en) 2009-04-23 2010-10-28 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
US8927551B2 (en) 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
CN102030770B (zh) * 2009-09-25 2012-10-31 北京大学 一种芳香硼酸酯化合物的制备方法
WO2011051342A1 (en) 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
US20130150346A1 (en) 2010-01-08 2013-06-13 Quest Ventures Ltd. Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
MX336742B (es) 2010-02-03 2016-01-29 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de acido graso.
EP2536285B1 (en) 2010-02-18 2018-04-25 vTv Therapeutics LLC Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
RS54761B1 (sr) 2010-06-24 2016-10-31 Gilead Sciences Pirazolo[1,5-a]pirimidini i-triazini kao antiviralni agensi
NZ608069A (en) 2010-10-06 2014-06-27 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
JP2012232924A (ja) * 2011-04-28 2012-11-29 Tosoh Corp 新規なナフチルボロン酸化合物及びその製造法
EP2723744B1 (en) 2011-06-27 2016-03-23 Janssen Pharmaceutica, N.V. 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
ES2708224T3 (es) * 2011-07-19 2019-04-09 Merck Sharp & Dohme 4-Imidazopiridazín-1-il-benzamidas y 4-imidazotriazín-1-il-benzamidas como inhibidores de Btk
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
WO2013096681A1 (en) 2011-12-22 2013-06-27 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines as antiviral agents
LT2838900T (lt) 2012-04-17 2019-11-11 Gilead Sciences Inc Junginiai ir būdai, skirti priešvirusinei terapijai
US9669035B2 (en) 2012-06-26 2017-06-06 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders
WO2014009305A1 (en) 2012-07-09 2014-01-16 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
WO2014086664A1 (en) * 2012-12-03 2014-06-12 F. Hoffmann-La Roche Ag Substituted triazole boronic acid compounds
CA2894399A1 (en) 2012-12-06 2014-06-12 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
JP2016510000A (ja) 2013-02-20 2016-04-04 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物およびその使用
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
WO2014134391A1 (en) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA2928658A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015164213A1 (en) 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
JP6615876B2 (ja) * 2014-06-26 2019-12-04 モナシュ ユニヴァーシティ 酵素相互作用薬剤
WO2016004166A1 (en) * 2014-07-02 2016-01-07 Xavier University Of Louisiana Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
CA2988147C (en) 2015-06-03 2023-06-13 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
CN106800569B (zh) * 2016-12-12 2019-04-16 上海中医药大学附属龙华医院 Atg类似物及其制备方法和应用
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324251A1 (en) 2016-09-08 2019-03-21 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018090717A1 (zh) * 2016-11-16 2018-05-24 上海中医药大学附属龙华医院 Atg类似物及其制备方法和应用
PL3759109T3 (pl) 2018-02-26 2024-03-04 Gilead Sciences, Inc. Podstawione związki pirolizyny jako inhibitory replikacji hbv
CN109180712B (zh) * 2018-08-08 2020-12-25 南京医科大学 一类2-茨醇的芳基硼酸酯衍生物及其应用
CN109096043B (zh) * 2018-08-24 2021-03-12 盐城师范学院 一种2,5-二溴碘苯的合成方法
FI3860998T3 (fi) 2018-10-05 2024-03-27 Annapurna Bio Inc Yhdisteitä ja koostumuksia apj-reseptorin aktiivisuuteen liittyvien tautitilojen hoitoon
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
FI4097099T3 (fi) 2020-02-07 2024-07-30 Gasherbrum Bio Inc Heterosyklisiä glp-1-agonisteja
US11643394B2 (en) 2020-04-30 2023-05-09 Icahn School Of Medicine At Mount Sinai Krüppel-like factor 15 (KLF15) small molecule agonists in kidney disease
EP4146639A1 (en) 2020-05-06 2023-03-15 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN112147273B (zh) * 2020-11-02 2022-08-16 北京市理化分析测试中心 一种检测油品中微量酸的方法
TW202241889A (zh) 2020-12-23 2022-11-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
PE20241335A1 (es) 2021-06-04 2024-07-03 Vertex Pharma N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
KR102567789B1 (ko) * 2021-06-08 2023-08-17 한국원자력의학원 신규한 벤조사이아졸 유도체 및 붕소 중성자 포획 요법에 있어서의 이의 용도
CR20230576A (es) 2021-06-14 2024-04-05 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cáncer
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
KR102668048B1 (ko) * 2022-08-02 2024-05-22 한국원자력의학원 신규한 벤조사이아졸 유도체 및 이의 용도

Family Cites Families (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4270537A (en) * 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1268808A (en) * 1985-07-23 1990-05-08 Alan G. Macdiarmid High capacity polyaniline electrodes
CH671400A5 (es) * 1986-12-17 1989-08-31 Nii Prikladnych
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) * 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) * 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
DE3807862A1 (de) * 1988-03-10 1989-09-21 Merck Patent Gmbh Smektische fluessigkristallphase
US5273680A (en) 1988-03-10 1993-12-28 Merck Patent Gesellschaft Mit Beschrankter Haftung Fluorinated oligophenyls and their use in liquid crystal materials
US5339163A (en) * 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) * 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
GB8829296D0 (en) * 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) * 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
DE59108963D1 (de) 1990-02-01 1998-05-20 Merck Patent Gmbh Verfahren zur Umsetzung von fluorierten Aromaten mit Elektrophilen
DE4014488A1 (de) 1990-05-07 1991-11-14 Merck Patent Gmbh Dioxaborinane und fluessigkristallines medium
US5190521A (en) * 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) * 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
DE59206518D1 (de) * 1991-02-25 1996-07-18 Hoffmann La Roche Flüssigkristalline Verbindungen mit endständigem 1-Alkinylrest
AU2014892A (en) 1991-04-30 1992-12-21 Procter & Gamble Company, The Liquid detergents with an aryl boronic acid
GB2258232B (en) 1991-07-31 1995-03-15 Merck Patent Gmbh Alkoxymethylene fluoroterphenyls and liquid crystalline medium
GB9118204D0 (en) * 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) * 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5328483A (en) * 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
CH683522A5 (de) 1992-03-13 1994-03-31 Hoffmann La Roche Verfahren zur Herstellung von Diarylen.
FR2688790B1 (fr) * 1992-03-23 1994-05-13 Rhone Poulenc Chimie Compositions a base de polyorganosiloxanes a groupements fonctionnels reticulables et leur utilisation pour la realisation de revetements anti-adhesifs.
FR2688783A1 (fr) 1992-03-23 1993-09-24 Rhone Poulenc Chimie Nouveaux borates d'onium ou de complexe organometallique amorceurs cationiques de polymerisation.
US5541061A (en) * 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
PL167141B1 (pl) 1992-05-12 1995-07-31 Wojskowa Akad Tech Sposób otrzymywania związków ciekłokrystalicznych zawierających pierścień 1,3-dioksa- -2-boranu
JP3255965B2 (ja) 1992-05-26 2002-02-12 昭和シェル石油株式会社 反強誘電性液晶化合物
DE4220065A1 (de) 1992-06-19 1993-12-23 Merck Patent Gmbh Verfahren zur Herstellung von Pyrimidin-Derivaten
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9220189D0 (en) * 1992-09-24 1992-11-04 Central Research Lab Ltd Dioxane derivatives
US5569189A (en) * 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
GB9220750D0 (en) * 1992-10-02 1992-11-18 Merck Patent Gmbh Liquid crystalline material forming ananisotropic
DE4236103A1 (de) * 1992-10-26 1994-04-28 Hoechst Ag Verfahren zur Kreuzkupplung von aromatischen Boronsäuren mit aromatischen Halogenverbindungen oder Perfluoralkylsulfonaten
US5334144A (en) * 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
TW240217B (es) 1992-12-30 1995-02-11 Glaxo Group Ltd
US5576220A (en) * 1993-02-19 1996-11-19 Arris Pharmaceutical Corporation Thin film HPMP matrix systems and methods for constructing and displaying ligands
FR2702485B1 (fr) 1993-03-10 1995-04-14 Rhone Poulenc Chimie Compositions à base de polyorganosiloxanes réticulables par voie cationique et leur utilisation dans le domaine de l'antiadhérence papier, de la protection des fibres optiques et des circuits imprimés.
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5417885A (en) * 1993-08-03 1995-05-23 Showa Shell Sekiyu Kabushiki Kaisha Antiferroelectric liquid crystal compound
US5431842A (en) 1993-11-05 1995-07-11 The Procter & Gamble Company Liquid detergents with ortho-substituted phenylboronic acids for inhibition of proteolytic enzyme
JPH07145174A (ja) 1993-11-22 1995-06-06 Takeda Chem Ind Ltd ジオキサボリナン系化合物、それらの製造方法、該化合物を含む液晶組成物および該組成物を用いた液晶光変調装置
JPH07165717A (ja) 1993-12-16 1995-06-27 Sumitomo Chem Co Ltd 複素環化合物およびその製造法
JPH07206715A (ja) 1994-01-21 1995-08-08 Sumitomo Chem Co Ltd 複素環化合物の製造法
DE19502178A1 (de) 1994-01-27 1995-08-03 Hoechst Ag Thiadiazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Vorprodukte zur Herstellung von Flüssigkristallen
WO1995024176A1 (en) * 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) * 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5643893A (en) * 1994-06-22 1997-07-01 Macronex, Inc. N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
JP3702426B2 (ja) 1994-08-03 2005-10-05 関東化学株式会社 トリフルオロメチルベンゼン誘導体および液晶組成物
FR2724660B1 (fr) 1994-09-16 1997-01-31 Rhone Poulenc Chimie Amorceurs de reticulation, par voie cationique, de polymeres a groupements organofonctionnels, compositions a base de polyorganosiloxanes reticulables et contenant ces amorceurs et application desdites compositions en antiadherence
JPH0892137A (ja) 1994-09-26 1996-04-09 Sumitomo Chem Co Ltd 芳香族エステル化合物、その製造法および用途
FR2727416A1 (fr) 1994-11-24 1996-05-31 Rhone Poulenc Chimie Nouveaux amorceurs cationiques thermoactivables, de polymerisation et/ou de reticulation et compositions monomeres et/ou polymeres fonctionnels les mettant en oeuvre
DE4445224B4 (de) 1994-12-17 2014-03-27 Merck Patent Gmbh Benzolderivate
US5599302A (en) * 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6271015B1 (en) * 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
JP3783246B2 (ja) 1995-07-18 2006-06-07 大日本インキ化学工業株式会社 ｐ−テルフェニル誘導体
DE59605843D1 (de) * 1995-07-28 2000-10-12 Rolic Ag Zug Photovernetzbare flüssigkristalline 1,2-Phenylen-Derivate
WO1997006124A1 (fr) 1995-08-09 1997-02-20 Chisso Corporation Derives du cyclohexane et compositions a cristaux liquides
US5893397A (en) * 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
FR2745288B1 (fr) 1996-02-27 1998-04-17 Adir Nouveaux derives de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9605334D0 (en) 1996-03-13 1996-05-15 British Nuclear Fuels Plc Biodecontamination reactor
JP3555325B2 (ja) 1996-04-12 2004-08-18 チッソ株式会社 ビアリール誘導体の製造方法
BG63255B1 (bg) 1996-06-03 2001-07-31 American Cyanamid Company 1,4-диарил-2-флуоро-2-бутенови инсектицидни и акарицидни средства
US5998673A (en) 1996-06-03 1999-12-07 American Cyanamid Company 1, 4-diaryl-2-fluoro-2-butene insecticidal and acaricidal agents
US5892131A (en) * 1997-05-29 1999-04-06 American Cyanamid Company Process for the preparation of pesticidal fluoroolefin compounds
US5849958A (en) 1997-03-17 1998-12-15 American Cyanamid Company 1,4,diaryl-2-fluoro-2-butene insecticidal and acaricidal agents
ZA974582B (en) 1996-06-03 1998-11-26 American Cyanamid Co Process and intermediate compounds for the preparation of pesticidal fluoroolefin compounds
CA2206192A1 (en) 1996-06-13 1997-12-13 F. Hoffmann-La Roche Ag Modulation of lc132 (opioid-like) receptor function
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
JPH1025261A (ja) 1996-07-09 1998-01-27 Chisso Corp フェノール誘導体の製造方法
BR9710780A (pt) * 1996-07-31 1999-08-17 Schionogi & Co Ltd Novos compostos de para-terefenila
JP3899557B2 (ja) 1996-08-21 2007-03-28 大日本インキ化学工業株式会社 フルオロビフェニル誘導体
FR2752582B1 (fr) * 1996-08-21 2003-06-13 Rhone Poulenc Chimie Compositions a base de polyorganosiloxanes a groupements fonctionnels reticulables et leur utilisation pour la realisation de revetements anti-adherents
JP4526605B2 (ja) * 1996-08-28 2010-08-18 チッソ株式会社 ラテラルハロゲン置換基を有する４環化合物および液晶組成物
US6177440B1 (en) * 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
US5925672A (en) 1996-12-06 1999-07-20 Neurosciences Research Foundation, Inc. Methods of treating mental diseases, inflammation and pain
FR2757530A1 (fr) 1996-12-24 1998-06-26 Rhodia Chimie Sa Utilisation pour la stereophotolithographie - d'une composition liquide photoreticulable par voie cationique comprenant un photoamorceur du type sels d'onium ou de complexes organometalliques
FR2757870B1 (fr) * 1996-12-30 1999-03-26 Rhodia Chimie Sa Utilisation de compositions silicones reticulables par voie cationique sous uv et d'un photoamorceur du type borate d'onium, pour le revetements de joints plats, notamment de joints de culasse
FR2758329B1 (fr) 1997-01-16 1999-02-12 Synthelabo Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
FR2758560B1 (fr) 1997-01-20 2000-02-04 Adir Nouveaux derives d'acides aminophenylboronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
WO1998035924A1 (fr) 1997-02-13 1998-08-20 Chisso Corporation Composes de cristaux liquides de structure bicyclo [1.1.1] pentane, composition pour cristaux liquides et elements d'affichages a cristaux liquides
DE19710614A1 (de) 1997-03-14 1998-09-17 Hoechst Ag (1,2,4)-Thiadiazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5993412A (en) * 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
CA2291055A1 (en) * 1997-06-13 1998-12-17 Northwestern University Inhibitors of .beta.-lactamases and uses therefor
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
DZ2769A1 (fr) 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
DE19909761A1 (de) 1998-04-17 1999-10-21 Merck Patent Gmbh Benzofuran- und Benzodifuran-Derivate
JP2000001463A (ja) 1998-06-12 2000-01-07 Dainippon Ink & Chem Inc ４−シアノベンゼン誘導体の製造方法
GB9814450D0 (en) 1998-07-04 1998-09-02 Sharp Kk Novel compounds
GB2339778A (en) 1998-07-17 2000-02-09 Secr Defence Terphenyl Liquid Crystals
WO2000020466A1 (de) 1998-10-01 2000-04-13 Targor Gmbh Katalysatorsystem
DE19857765A1 (de) * 1998-12-15 2000-06-21 Clariant Gmbh Verfahren zur Herstellung von para-Oxadiazolyl-phenyl-boronsäuren
DE19858594A1 (de) 1998-12-18 2000-06-21 Merck Patent Gmbh Verfahren zur Herstellung von Cyanbenzolboronsäuren
DE59904576D1 (de) * 1998-12-19 2003-04-17 Basell Polyolefine Gmbh Verfahren zur herstellung von mono- oder di-organo-boranen
BR0007532A (pt) * 1999-01-13 2001-11-20 Univ New York State Res Found Métodos para identificar inibidores de proteìnaquinase, para testar compostos para umacapacidade de inibir a atividade de proteìnaquinase e para inibir uma proteìna quinase, inibidorde proteìna tirosina quinase não peptìdica, e,método de tratar uma condição responsiva a uminibidor de proteìna quinase em um paciente
JP4507294B2 (ja) 1999-05-27 2010-07-21 チッソ株式会社 ビアリール誘導体の製造方法
WO2001021606A1 (en) 1999-09-21 2001-03-29 Qinetiq Limited Liquid crystal compounds
US6309406B1 (en) * 1999-11-24 2001-10-30 Hamit-Darwin-Fresh, Inc. Apparatus and method for inducing epileptic seizures in test animals for anticonvulsant drug screening
MXPA02005465A (es) * 1999-12-03 2003-10-15 Ono Pharmaceutical Co Derivados de triazaspiro(5.5)undecano y composiciones farmaceuticas que los comprenden, como un ingrediente activo.
US20030096854A1 (en) * 2002-06-12 2003-05-22 Ho-Shen Lin Substituted tricyclics
FR2805273B1 (fr) * 2000-02-18 2006-08-11 Rhodia Chimie Sa Traitement de surface de materiau plastique avec une composition a fonctions reactives polymerisable et/ou reticulable
DE10009714A1 (de) 2000-03-01 2001-09-06 Targor Gmbh Verfahren zur Herstellung von Mono- oder Di-organo-boranen
GB2362882A (en) 2000-06-02 2001-12-05 Sharp Kk Liquid crystalline optionally laterally fluorinated terphenyl with chiral 3,4-di[(un)saturated-alkoxy]butoxy or 1,4-di[(un)saturated-alkoxy]but-2-oxy terminus
US20040039129A1 (en) 2000-08-16 2004-02-26 Hall Dennis G. Non-pressurized methods for the preparation of conjugrated solid supports for boronic acids
ES2288982T3 (es) * 2000-08-23 2008-02-01 Eli Lilly And Company Derivados de acido oxazolil-ariloxiacetico y su uso como agonistas ppar.
US6927216B2 (en) * 2000-10-03 2005-08-09 Bristol-Myers Squibb Pharma Company Cyclic sulfonyl compounds as inhibitors of metalloproteases
DE60140559D1 (de) * 2000-10-05 2009-12-31 Millenium Pharmaceuticals Inc 32144, eine humane fettsäureamid-hydrolase und deren verwendungen
GB0100110D0 (en) 2001-01-04 2001-02-14 Univ Leeds Modulation of calcium channel activity
US20040235792A1 (en) * 2001-01-20 2004-11-25 Deadman John J Serine protease inhibitors compromising a hydrogen-bond acceptor
JP4721027B2 (ja) 2001-03-29 2011-07-13 Ｄｉｃ株式会社 フェニルピリミジン誘導体の製造方法
US20030022864A1 (en) 2001-04-24 2003-01-30 Ishaq Khalid S. 9-[(5-dihydroxyboryl)-pentyl] purines, useful as an inhibitor of inflammatory cytokines
US6617125B2 (en) * 2001-06-29 2003-09-09 Perkinelmer Life Sciences, Inc. Compositions for enhanced catalyzed reporter deposition
US6858592B2 (en) * 2001-06-29 2005-02-22 Genzyme Corporation Aryl boronic acids for treating obesity
DE60205824T2 (de) * 2001-07-09 2006-05-18 Merck Patent Gmbh Thienothiophenderivate
US7217701B2 (en) * 2001-10-11 2007-05-15 Katsuhiko Mikoshiba Intracellular calcium concentration increase inhibitors
KR20050034609A (ko) * 2001-10-12 2005-04-14 다우 글로벌 테크놀로지스 인크. 금속 착물 조성물 및 폴리디엔을 제조하기 위한촉매로서의 이의 용도
ATE360054T1 (de) * 2001-11-07 2007-05-15 Merck Patent Gmbh Flüssigkristalline verbindung, flüssigkristallines medium und flüssigkristallanzeige
GB0126844D0 (en) * 2001-11-08 2002-01-02 Qinetiq Ltd Novel compounds
WO2003045228A2 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
JPWO2003050201A1 (ja) * 2001-12-12 2005-04-21 株式会社トクヤマ 有機エレクトロルミネッセンス素子材料
DE10201764A1 (de) 2002-01-18 2003-07-31 Bayer Cropscience Ag Substituierte 4-Aminopyridin-Derivate
WO2003064484A1 (en) 2002-01-28 2003-08-07 Dow Global Technologies Inc. Metal complex compositions based on cobalt and their use as polymerization catalyst for olefins and dienes
DE10206759A1 (de) * 2002-02-19 2003-08-28 Dragoco Gerberding Co Ag Synergistische Mischungen von 1,2-Alkandiolen
DE10211597A1 (de) * 2002-03-15 2003-10-02 Merck Patent Gmbh Verfahren zur Herstellung von Ringverbindungen
WO2003105860A1 (en) * 2002-06-14 2003-12-24 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
PL375195A1 (en) * 2002-06-27 2005-11-28 Astellas Pharma Inc. Aminoalcohol derivatives
EP1388538B1 (en) 2002-07-09 2010-09-01 Merck Patent GmbH Polymerisation Initiator
US20040115475A1 (en) * 2002-08-14 2004-06-17 Matsushita Electric Industrial Co., Ltd. Aromatic methylidene compound, methylstyrul compound for producing the same, production electroluminescent element
CA2506026A1 (en) 2002-11-14 2004-05-27 The Scripps Research Institute Crystalline form of fatty acid amine hydrolase (faah)
ATE366247T1 (de) * 2002-11-27 2007-07-15 Merck Patent Gmbh Tetrahydropyran-derivate
US6924269B2 (en) * 2002-12-04 2005-08-02 Vdf Futureceuticals, Inc. Enzyme inhibitors and methods therefor
US7390806B2 (en) 2002-12-18 2008-06-24 Anacor Pharmaceuticals, Inc. Antibiotics containing borinic acid complexes and methods of use
US7456169B2 (en) * 2003-02-27 2008-11-25 Abbott Laboratories Inc. Heterocyclic kinase inhibitors
EP1599475A2 (en) * 2003-03-06 2005-11-30 Eisai Co., Ltd. Jnk inhibitors
WO2004080989A1 (ja) 2003-03-10 2004-09-23 Sumitomo Chemical Company Limited フラン化合物の製造方法
JP2006520397A (ja) * 2003-03-14 2006-09-07 アストラゼネカ アクチボラグ 新規融合トリアゾロン類及びその使用
JP2004292766A (ja) * 2003-03-28 2004-10-21 Tokuyama Corp 有機エレクトロルミネッセンス素子材料
DE10325438A1 (de) * 2003-05-21 2004-12-09 Bayer Cropscience Ag Difluormethylbenzanilide
AR045690A1 (es) 2003-06-03 2005-11-09 Rib X Pharmaceuticals Inc Compuestos biaril heterociclicos y metodos para preparar y utilizar los mismos
JP2007505950A (ja) 2003-06-10 2007-03-15 フルクラム・ファーマシューティカルズ・インコーポレーテッド β−ラクタマーゼ阻害剤およびその使用方法
BRPI0411582A (pt) 2003-06-16 2006-08-08 Anacor Pharmaceuticals Inc substáncias terapêuticas contendo boro hidroliticamente resistentes e método de uso
DE10337497A1 (de) * 2003-08-14 2005-03-10 Bayer Cropscience Ag 4-Biphenylsubstituierte-Pyrazolidin-3,5-dion-Derivate
US20070293542A1 (en) 2003-10-16 2007-12-20 Cali Brian M Selective Cox-2 Inhibitors
WO2005041904A2 (en) 2003-10-31 2005-05-12 Fulcrum Pharmaceuticals, Inc. Inhibitors of coronavirus protease and methods of use thereof
JP2007520453A (ja) * 2003-11-10 2007-07-26 マイクロビア インコーポレーテッド ４−ビアリーリル−１−フェニルアゼチジン−２−オン
US20070010559A1 (en) * 2003-11-25 2007-01-11 Novo Nordisk A/S Indole derivatives for use as chemical uncoupler
JP4491666B2 (ja) 2003-12-02 2010-06-30 東ソー株式会社 フルオレン骨格を有するアリールアミン誘導体の製造方法とその合成中間体
GB2410745B (en) 2004-02-06 2007-07-25 Merck Patent Gmbh Cholestanyl derivatives
NZ549046A (en) * 2004-02-13 2010-06-25 Banyu Pharma Co Ltd Fused-ring 4-oxopyrimidine derivative
GB0403744D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
DE102004041532A1 (de) 2004-08-27 2006-03-02 Bayer Cropscience Ag Biphenylthiazolcarboxamide
DE102004041530A1 (de) * 2004-08-27 2006-03-02 Bayer Cropscience Ag Biphenylthiazolcarboxamide
WO2006038100A1 (en) * 2004-10-08 2006-04-13 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
CA2585766A1 (en) 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
US20080269204A1 (en) 2004-11-01 2008-10-30 Tatyana Dyakonov Compounds and Methods of Use Thereof
US20080319044A1 (en) 2004-11-01 2008-12-25 Nuada, Llc Compounds and Methods of Use Thereof
US20090209492A1 (en) 2004-11-12 2009-08-20 Trustees Of Tufts College Lipase Inhibitors
DE102005023834A1 (de) * 2004-11-20 2006-05-24 Bayer Healthcare Ag Substituierte[(Phenylethanoyl)amino]benzamide
US7425281B2 (en) * 2004-12-02 2008-09-16 Displaytech, Inc. Liquid crystal compositions comprising an organogermanium compound and methods for using the same
US7553496B2 (en) * 2004-12-21 2009-06-30 University Of Kentucky Research Foundation VEGF-A as an inhibitor of angiogenesis and methods of using same
CN101103026A (zh) 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
EP1851197A2 (en) * 2005-02-09 2007-11-07 Microbia, Inc. Phenylazetidinone derivatives
ES2540966T3 (es) * 2005-02-16 2015-07-15 Anacor Pharmaceuticals, Inc. Compuestos biocidas de boronoftalida
WO2006091799A2 (en) 2005-02-22 2006-08-31 Sumation Co. Ltd. High bandgap arylene polymers
US7589066B2 (en) 2005-03-11 2009-09-15 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
GB2424881B (en) 2005-04-07 2010-11-24 Merck Patent Gmbh Halophenyl derivatives of bisalkylfluorene
JP4792796B2 (ja) 2005-04-08 2011-10-12 東ソー株式会社 ２，３−ジハロビフェニレン誘導体、その前駆化合物及び製造方法
WO2006122186A2 (en) 2005-05-10 2006-11-16 Microbia, Inc. 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
WO2006124713A2 (en) 2005-05-13 2006-11-23 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-ones
EP1726581A1 (en) 2005-05-25 2006-11-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Synthesis of novel monomers containing the Trifluorovinylidene-group and the Cyanato-group and polymers thereof
CA2610659A1 (en) 2005-06-14 2006-12-21 Merck Frosst Canada Ltd. Reversible inhibitors of monoamine oxidase a and b
KR100659088B1 (ko) * 2005-07-15 2006-12-21 삼성에스디아이 주식회사 디플루오로피리딘계 화합물 및 이를 이용한 유기 발광 소자
TW200740823A (en) * 2005-08-01 2007-11-01 Ihara Chemical Ind Co Oxadiazole-substituted Sym-triindole derivative and organic el element employing the same
DE102005037925A1 (de) 2005-08-11 2007-02-15 Merck Patent Gmbh Hydro-cyclopenta[a]naphthaline
WO2007028104A2 (en) * 2005-09-02 2007-03-08 Auspex Pharmaceuticals, Inc. Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
EP1926706B1 (en) * 2005-09-13 2012-03-21 Bayer CropScience AG Pesticide bi-phenyl-amidine derivatives
PL1959951T3 (pl) * 2005-12-01 2010-06-30 Hoffmann La Roche Heteroarylo-podstawione pochodne piperydyny jako inhibitory l-cpt1
JP5001949B2 (ja) 2005-12-02 2012-08-15 サッチェム，インコーポレイテッド 陰イオン交換置換クロマトグラフィー方法および陰イオン交換置換クロマトグラフィー方法における置換剤化合物として用いられる陰イオン性有機化合物
BRPI0621279B1 (pt) * 2005-12-30 2021-07-20 Anacor Pharmaceuticals, Inc Moléculas pequenas contendo boro
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
GB0602046D0 (en) * 2006-02-01 2006-03-15 Smithkline Beecham Corp Compounds
DK2719388T3 (da) * 2006-02-16 2019-05-13 Anacor Pharmaceuticals Inc Borholdige små molekyler som antiinflammatoriske midler
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
DE102007009944B4 (de) 2006-03-15 2016-04-28 Merck Patent Gmbh Flüssigkristallines Medium und seine Verwendung
EP2012782A1 (en) 2006-04-13 2009-01-14 Aegera Therapeutics Inc. USE OF IMIDAZO[2,1-b)]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN
JP5145753B2 (ja) 2006-04-20 2013-02-20 Ｊｎｃ株式会社 フルオロイソプロピル基を側鎖として有する化合物およびこれを用いた液晶組成物
KR20090029797A (ko) * 2006-06-12 2009-03-23 아나코르 파마슈티칼스 인코포레이티드 치주질환의 치료를 위한 화합물
US7838542B2 (en) * 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
KR20090033417A (ko) 2006-07-27 2009-04-03 씨브이 쎄러퓨틱스, 인코포레이티드 중독의 치료에서의 ａｌｄｈ-2 저해제
US8034940B2 (en) * 2006-08-09 2011-10-11 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2008020920A1 (en) * 2006-08-15 2008-02-21 Duke University Ros-sensitive iron chelators and methods of using the same
EP2052055B1 (de) 2006-08-16 2011-07-06 Merck Patent GmbH Cyclohexen-verbindungen für flüssigkristalline mischungen
DE502007004625D1 (de) * 2006-09-13 2010-09-16 Merck Patent Gmbh Fluorphenyl-Verbindungen für flüssigkristalline Mischungen
WO2008039829A2 (en) 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Diphenylheterocycle cholesterol absorption inhibitors
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
AP2780A (en) 2006-10-18 2013-09-30 Pfizer Prod Inc Biaryl ether urea compounds
KR101435236B1 (ko) 2007-01-24 2014-08-28 제이엔씨 석유 화학 주식회사 액정성 화합물, 액정 조성물 및 액정 표시 소자
KR101455428B1 (ko) 2007-02-28 2014-10-27 제이엔씨 석유 화학 주식회사 Ｃｆ2ｏ 결합기를 갖는 5 고리 액정 화합물, 액정 조성물 및 액정 표시 소자
GB2460784A (en) * 2007-03-07 2009-12-16 Dong A Pharmtech Co Ltd Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators,method of the same,and pharmaceutical composition
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009011904A1 (en) 2007-07-19 2009-01-22 Renovis, Inc. Compounds useful as faah modulators and uses thereof
EP2282742A1 (en) 2008-04-09 2011-02-16 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
CN102015585B (zh) 2008-05-08 2013-06-19 住友化学株式会社 不饱和有机化合物的制造方法
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine

Also Published As

Publication number Publication date
US20110172186A1 (en) 2011-07-14
AR072249A1 (es) 2010-08-18
CN102046179B (zh) 2015-01-14
US20150368278A1 (en) 2015-12-24
AU2009233711A1 (en) 2009-10-15
TW201000107A (en) 2010-01-01
WO2009126691A1 (en) 2009-10-15
AU2009233711B2 (en) 2015-02-12
CN102046179A (zh) 2011-05-04
EP2282742A1 (en) 2011-02-16
US8957049B2 (en) 2015-02-17
IL208536A0 (en) 2010-12-30
JP2011516564A (ja) 2011-05-26
JP5637982B2 (ja) 2014-12-10
CL2009000870A1 (es) 2010-06-25
CA2721060A1 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
PE20091838A1 (es) Inhibidores de amida hidrolasa de acido graso
EA200970296A1 (ru) Содержащие диариловый эфир соединения мочевины
PE20090903A1 (es) Derivados de acido azabifenilaminobenzoico como inhibidores de la dihidroorotato deshidrogenasa
PE20061099A1 (es) Compuestos de piridil acido acetico como inhibidores de peptidasa
PE20091002A1 (es) Analogos dipeptidos como inhibidores del factor de coagulacion
MA33880B1 (fr) Nouveaux composés efficaces comme inhibiteurs de la xanthine oxydase, leur procédé de préparation et composition pharmaceutique les contenant
ATE484504T1 (de) Imidazo ä1,2-aüpyridin-2-carboxamid-derivate, herstellungsverfahren und ihre verwendung für therapeutika
RU2012123154A (ru) Способы лечения синдрома фибромиалгии
EA201391532A1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EA200970605A1 (ru) Ингибиторы mapk/erk-киназ
UY32454A (es) SOLUCIONES AMORTIGUADAS DE AMINOALCOHOL DE N-(n-butil) TRIAMIDA TIOFOSFORICA (NBPT) Y FERTILIZANTES DE UREA QUE UTILIZAN DICHAS SOLUCIONES COMO INHIBIDORES DE LA UREASA
MA32391B1 (fr) Activateurs de la glucokinase
ECSP11010889A (es) INHIBIDORES DE cMET
EA200700931A1 (ru) Новые производные дикарбоновых кислот
PE20061422A1 (es) Tigeciclina y metodos para preparar 9-nitrominociclina
MX2013014843A (es) Oxazepinas como moduladores del canal de iones.
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
EA201100354A1 (ru) Полиморф в n-(2-аминофенил)-4-[n-(пиридин-3-ил)-метоксикарбониламинометил]бензамида (ms-275)
NZ619076A (en) Isoxazolines as inhibitors of fatty acid amide hydrolase
EA201000436A1 (ru) Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью
EA201071040A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40
MA32579B1 (fr) Derives de carbamates d'alkylthiazoles, leur preparation et leur utilisation comme inhbiteurs de l'enzyme faah
RU2012155118A (ru) Способы лечения биполярного расстройства
PE20081395A1 (es) Derivados de aril sulfamida y metodos para su uso
BR112015011974A2 (pt) derivados de azaquinazolina carboxamida

Legal Events

Date Code Title Description
FA Abandonment or withdrawal